ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has…
Author: Business Wire
Acute Ocular Pain Market Analysis and Forecast, 2023-2025 & 2025-2035 with Focus on the Patent and Clinical Trials Landscape – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Acute Ocular Pain Market – A Global and Regional Analysis: Focus on Indication and Region – Analysis and Forecast, 2025-2035” report has been added to ResearchAndMarkets.com’s offering. The global acute ocular pain market …
STAAR Surgical Announces Appointment of Deborah Andrews as Chief Financial Officer, Forms Capital Stewardship Committee of the Board of Directors
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Deborah Andrews has been appointed …
Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it wil…
ForSight Robotics Secures $125M in Series B Funding, Addressing Global Surgeon Shortage and Exploding Demand for Ophthalmic Surgery
YOKNEAM ILLIT, Israel–(BUSINESS WIRE)– #AI–ForSight Robotics secures $125M Series B funding, led by Eclipse, to tackle global vision crisis and perform robotic cataract surgery clinical trials.
Meta and IngenioSpec Settled ITC Dispute on Electronic Eyewear Products
WACO, Texas–(BUSINESS WIRE)–Meta and IngenioSpec Resolve Patent Dispute on Smart Glasses Technology.
ZEISS Vision Care US Names Healthcare Industry Veteran Gary Rosenblum as President and Chief Executive Officer
HEBRON, Ky.–(BUSINESS WIRE)–ZEISS Vision Care, one of the world’s leading manufacturers of eyeglass lenses and ophthalmic instruments, announced today that Gary Rosenblum has been named President and Chief Executive Officer of ZEISS Vision Care US, e…
Qlaris Bio to Present New Clinical and Preclinical Data on QLS-111 at 2025 World Glaucoma Congress
DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc., a clinical‐stage biotechnology company dedicated to developing first‐in‐class therapies for glaucoma, today announced that new data from studies of its lead investigational compound QLS-111 will be pres…
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neu…
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
TORONTO–(BUSINESS WIRE)– #AlconCanada–Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in Canada. Pa…
Alcon annonce l’arrivée de Clareon PanOptix Pro au Canada, une lentille intraoculaire réduisant la dispersion de la lumière comme aucune autre LIO trifocale
TORONTO–(BUSINESS WIRE)–Alcon (SIX/NYSE : ALC), le chef de file mondial en matière de soins oculaires dédié à aider les gens à voir avec clarté, a annoncé aujourd’hui l’approbation de la lentille intraoculaire (LIO) ClareonMD PanOptix MD Pro pour les…
Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+L…
Sling Therapeutics Appoints Ken Lock as Chief Commercial Officer
ANN ARBOR, Mich.–(BUSINESS WIRE)–Sling Therapeutics Appoints Ken Lock as Chief Commercial Officer
PolyActiva Appoints Jerry St. Peter as CEO and Secures $25M Series C Financing to Accelerate US Expansion and Clinical Advancement of PREZIA™ Technology Platform
MELBOURNE, Australia & FORT WORTH, Texas–(BUSINESS WIRE)–PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, today announced two major milestones …
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications
NASHVILLE, Tenn.–(BUSINESS WIRE)–Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Dire…
Amaros Closes Series A Financing, Expands Advisory Board to Accelerate Market Entry of the EvidenceEngine™ Ophthalmic AI Platform
ATHERTON, Calif.–(BUSINESS WIRE)–Amaros Inc. (www.amaros.ai), a leader in ophthalmic intelligence and the developer of AI-powered EvidenceEngine platform, today announced the successful close of its Series A financing. Backed by a select group of new…
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑mediated and metabolic diseases, today announced the res…
Sightview Names Tycene Fritcher as CEO
DURHAM, N.C.–(BUSINESS WIRE)– #EHR–Sightview, the only electronic health record and practice management partner focused solely on eyecare, has named Tycene Fritcher as CEO.
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
RAHWAY, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, fo…
HOYA Vision Care presenta gli aggiornamenti dal Convegno annuale della Association for Research in Vision and Ophthalmology (ARVO) 2025
SALT LAKE CITY–(BUSINESS WIRE)–HOYA Vision Care (https://www.hoyavision.com/) oggi ha annunciato una nuova evidenza clinica proveniente da tre studi clinici chiave che evidenziano l’impatto della tecnologia D.I.M.S. (Defocus Incorporated Multiple Seg…